重组人C1酯酶抑制剂(conestat alfa)预防COVID-19住院患者重症SARS-CoV-2感染:随机平行组开放标签多中心试点试验(PROTECT-COVID-19)研究方案结构化摘要
本研究为研究者发起的2a期随机、开放标签、平行组、多中心试点试验,旨在评估conestat alfa联合标准治疗在改善COVID-19肺部疾病患者疾病严重程度和短期结局方面的疗效与安全性。计划随机约120例患者(活性治疗组80例,标准治疗组40例),主要终点为入组后第7天采用改良WHO临床改善序贯量表评估的疾病严重程度。
要点
- conestat alfa在标准治疗基础上用于住院COVID-19患者,旨在评估其改善疾病严重程度和短期结局的疗效与安全性。
- 试验采用2:1随机、开放标签设计,计划入组约120例,主要终点为第7天改良WHO序贯量表评分。
- 干预方案为conestat alfa 8400 U负荷后每8小时4200 U,72小时内共9次缓慢静脉注射。
核心结论
- 本试验旨在评估conestat alfa联合标准治疗能否改善COVID-19住院患者的疾病严重程度和短期结局。
研究设计与样本
- 研究者发起的随机(2:1)、开放标签、平行组、对照、多中心2a期临床试验。
- 计划在瑞士3家、巴西1家、墨西哥1家医院开展,拟随机约120例(活性组80例,标准治疗组40例)。
关键数值与推荐
- 主要终点为入组后第7天采用改良WHO临床改善序贯量表(去掉0分,合并6和7分)从1分(活动无限制)到7分(死亡)评估的疾病严重程度。
- 次要终点包括14天内临床改善时间(WHO序贯量表改善2分或出院)、14天存活且无需有创或无创通气的比例、14天内无急性肺损伤(PaO2/FiO2≤300mmHg)的比例。
- 干预组给予conestat alfa 8400 U负荷后每8小时4200 U,72小时内共9次缓慢静脉注射(5-10分钟),对照组仅接受标准治疗。
- 入选标准包括年龄18-85岁、胸部CT或X线显示肺部受累、COVID-19症状持续时间≤10天,以及至少一项进展至机械通气的危险因素。
- 计划在40例和80例患者后进行两次中期分析,采用Pocock调整界值αp=0.0221,并允许样本量调整。
临床怎么用
- 若试验证实有效,conestat alfa可能为COVID-19住院患者提供一种多靶点炎症抑制治疗选择。
局限性
- 开放标签设计,参与者和结局评估者均未设盲。
- 试点试验样本量较小(约120例),研究结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study objective is to investigate the efficacy and safety of conestat alfa in improving disease severity and short-term outcome in COVID-19 patients with pulmonary disease. TRIAL DESIGN: This study is an investigator-initiated, randomized (2:1 ratio), open-label, parallel-group, controlled, multi-center, phase 2a clinical trial. PARTICIPANTS: This trial is conducted in 3 hospitals in Switzerland, 1 hospital in Brazil and 1 hospital in Mexico (academic and non-academic). All patients with confirmed SARS-CoV-2 infection requiring hospitalization for at least 3 calendar days for severe COVID-19 will be screened for study eligibility. INCLUSION CRITERIA: - Signed informed consent - Age 18-85 years - Evidence of pulmonary involvement on CT scan or X-ray of the chest - Duration of symptoms associated with COVID-19 ≤ 10 days - At least one of the following risk factors for progression to mechanical ventilation on the day of enrolment: 1) Arterial hypertension 2) ≥ 50 years 3) Obesity (BMI ≥ 30 kg/m2) 4) History of cardiovascular disease 5) Chronic pulmonary disease 6) Chronic renal disease 7) C-reactive protein > 35mg/L 8) Oxygen saturation at rest of ≤ 94% when breathing ambient air Exclusion criteria: - Incapacity or inability to provide informed consent - Contraindications to the class of drugs under investigation (C1 esterase inhibitor) - Treatment with tocilizumab or another IL-6R or IL-6 inhibitor before enrolment - History or suspicion of allergy to rabbits - Pregnancy or breast feeding - Active or anticipated treatment with any other complement inhibitor - Liver cirrhosis (any Child-Pugh score) - Admission to an ICU on the day or anticipated within the next 24 hours of enrolment - Invasive or non-invasive ventilation - Participation in another study with any investigational drug within the 30 days prior to enrolment - Enrolment of the study investigators, their family members, employees and other closely related or dependent persons INTERVENTION AND COMPARATOR: Patients randomized to the experimental arm will receive conestat alfa in addition to standard of care (SOC). Conestat alfa (8400 U followed by 4200 U every 8 hours) will be administered as a slow intravenous injection (5-10 minutes) over a 72-hour period (i.e. 9 administrations in total). The first conestat alfa treatment will be administered on the day of enrolment. The control group will receive SOC only. SOC treatment will be administered according to local institutional guidelines, including supplemental oxygen, antibiotics, corticosteroids, remdesivir, and anticoagulation. MAIN OUTCOMES: The primary endpoint of this trial is disease severity on day 7 after enrolment assessed by an adapted WHO Ordinal Scale for Clinical Improvement (score 0 will be omitted and score 6 and 7 will be combined) from 1 (no limitation of activities) to 7 (death). Secondary outcomes include (i) the time to clinical improvement (time from randomization to an improvement of two points on the WHO ordinal scale or discharge from hospital) within 14 days after enrolment, (ii) the proportion of participants alive and not having required invasive or non-invasive ventilation at 14 days after enrolment and (iii) the proportion of subjects without an acute lung injury (defined by PaO2/FiO2 ratio of ≤300mmHg) within 14 days after enrolment. Exploratory outcomes include virological clearance, C1 esterase inhibitor pharmacokinetics and changes in routine laboratory parameters and inflammatory proteins. RANDOMISATION: Subjects will be randomised in a 2:1 ratio to treatment with conestat alfa in addition to SOC or SOC only. Randomization is performed via an interactive web response system (SecuTrial®). BLINDING (MASKING): In this open-label trial, participants, caregivers and outcome assessors are not blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): We will randomise approximately 120 individuals (80 in the active treatment arm, 40 in the SOC group). Two interim analyses after 40 and 80 patients are planned according to the Pocock adjusted levels αp = 0.0221. The results of the interim analysis will allow adjustment of the sample size (Lehmacher, Wassmer, 1999). TRIAL STATUS: PROTECT-COVID-19 protocol version 3.0 (July 07 2020). Participant recruitment started on July 30 2020 in one center (Basel, Switzerland, first participant included on August 06 2020). In four of five study centers patients are actively recruited. Participation of the fifth study center (Mexico) is anticipated by mid December 2020. Completion of trial recruitment depends on the development of the SARS-CoV-2 pandemic. TRIAL REGISTRATION: Clinicaltrials.gov, number: NCT04414631 , registered on 4 June 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Urwyler P, Charitos P, Moser S, et al. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials. 2021. PMID: 33397449. doi:10.1186/s13063-020-04976-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。